GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Wuhan Hvsen Biotechnology Co Ltd (SZSE:300871) » Definitions » Price-to-Owner-Earnings

Wuhan Hvsen Biotechnology Co (SZSE:300871) Price-to-Owner-Earnings : (As of May. 22, 2024)


View and export this data going back to 2020. Start your Free Trial

What is Wuhan Hvsen Biotechnology Co Price-to-Owner-Earnings?

As of today (2024-05-22), Wuhan Hvsen Biotechnology Co's share price is ¥14.75. Wuhan Hvsen Biotechnology Co does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for Wuhan Hvsen Biotechnology Co's Price-to-Owner-Earnings or its related term are showing as below:


SZSE:300871's Price-to-Owner-Earnings is not ranked *
in the Biotechnology industry.
Industry Median: 33.52
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-22), Wuhan Hvsen Biotechnology Co's share price is ¥14.75. Wuhan Hvsen Biotechnology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-0.09. Therefore, Wuhan Hvsen Biotechnology Co's PE Ratio for today is At Loss.

As of today (2024-05-22), Wuhan Hvsen Biotechnology Co's share price is ¥14.75. Wuhan Hvsen Biotechnology Co's EPS without NRI for the trailing twelve months (TTM) ended in was ¥0.06. Therefore, Wuhan Hvsen Biotechnology Co's PE Ratio without NRI for today is 245.83.

During the past 8 years, Wuhan Hvsen Biotechnology Co's highest PE Ratio without NRI was 262.17. The lowest was 23.77. And the median was 39.56.


Wuhan Hvsen Biotechnology Co Price-to-Owner-Earnings Historical Data

The historical data trend for Wuhan Hvsen Biotechnology Co's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Wuhan Hvsen Biotechnology Co Price-to-Owner-Earnings Chart

Wuhan Hvsen Biotechnology Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial - - - - -

Wuhan Hvsen Biotechnology Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Wuhan Hvsen Biotechnology Co's Price-to-Owner-Earnings

For the Biotechnology subindustry, Wuhan Hvsen Biotechnology Co's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Wuhan Hvsen Biotechnology Co's Price-to-Owner-Earnings Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Wuhan Hvsen Biotechnology Co's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where Wuhan Hvsen Biotechnology Co's Price-to-Owner-Earnings falls into.



Wuhan Hvsen Biotechnology Co Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

Wuhan Hvsen Biotechnology Co's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=14.75/-2.01
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Wuhan Hvsen Biotechnology Co  (SZSE:300871) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


Wuhan Hvsen Biotechnology Co Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of Wuhan Hvsen Biotechnology Co's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


Wuhan Hvsen Biotechnology Co (SZSE:300871) Business Description

Traded in Other Exchanges
N/A
Address
218 Zhangbai Road, Dongxihu District, Hubei Province, Wuhan, CHN, 430042
Wuhan Hvsen Biotechnology Co Ltd is engaged in research and development, production and sales of veterinary drugs (including chemical drug preparations, raw materials, and Chinese medicine preparations), feed and additives. It produces tylvalosin raw material, various tylvalosin preparations, florfenicol preparations and other macrolides products.

Wuhan Hvsen Biotechnology Co (SZSE:300871) Headlines

No Headlines